Product Information
METHOTREXATE 2.5 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.1577 per EA under NDC 00904714110. Its NADAC has been published 268 times since Aug 18, 2021.
FDA first approved this application on Jan 13, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
2.5 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904714110
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHOTREXATEApproval Type
Generic (ANDA)
FDA Application
ANDA207812FDA Approved
1/13/2017
TE Code
AB
On Market Since
2/9/2017
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 2.5 MG TABLET has been published 268 times since Aug 18, 2021, and over the history we have for it it has declined 54.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1577 per EA |
|---|---|
| All-time high | $0.3498 (Sep 15, 2021) |
| All-time low | $0.1507 (May 22, 2024) |
| 52-week high | $0.1645 |
| 52-week low | $0.1530 |
| Median price | $0.1836 |
| Average price | $0.2049 |
| Largest weekly change | +41.4% (Jun 19, 2024) |
| Weeks tracked | 268 |
| Tracking since | Aug 18, 2021 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHOTREXATE 2.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 2.5 MG TABLET, manufactured by Major Pharmaceuticals, is $0.1577 per EA (NDC 00904714110), effective Sep 30, 2026.
How has the price of METHOTREXATE 2.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 2.5 MG TABLET has declined 54.9%. It has been tracked across 268 weekly CMS publications since Aug 18, 2021.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 2.5 MG TABLET?
Since Aug 18, 2021, the NADAC for METHOTREXATE 2.5 MG TABLET has ranged from a low of $0.1507 (May 22, 2024) to a high of $0.3498 (Sep 15, 2021), with a median of $0.1836 per EA.
Are there cheaper alternatives to METHOTREXATE 2.5 MG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as METHOTREXATE 2.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures METHOTREXATE 2.5 MG TABLET?
METHOTREXATE 2.5 MG TABLET (NDC 00904714110) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.